Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501719 | 0.80 | KDM4E (0.33) | ALDH1A1MAPTHPGDKDM4EGAA | |
| SCHEMBL26501683 | 0.80 | ALDH1A1 (0.33) | ALDH1A1MAPTHPGDKDM4EGAA | |
| SCHEMBL26501659 | 0.73 | SLC40A1 (0.34) | ALDH1A1KDM4EGAAPOLB | |
| SCHEMBL26501648 | 0.73 | DHFR (0.47) | ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL26501744 | 0.72 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDKDM4EGAA | |
| SCHEMBL26501799 | 0.72 | RAB9A (0.39) | ALDH1A1MAPTHPGDKDM4EGAA | |
| SCHEMBL26501770 | 0.71 | KDM4E (0.31) | ALDH1A1MAPTHPGDKDM4EGAA | |
| SCHEMBL26501656 | 0.69 | MEN1 (0.40) | GAALMNA | |
| SCHEMBL27420741 | 0.69 | LMNA (0.40) | ALDH1A1MAPTHPGDKDM4EGAA | |
| SCHEMBL12394773 | 0.69 | ALDH1A1 (0.35) | ALDH1A1MAPTHPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | ALDH1A1 715/4885MAPT 1819/4885HPGD 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.